Once thought purely degenerative in nature, CAVD progression is now believed to constitute an active cellular process occurring within the aortic valve leaflets. Broadly speaking, CAVD pathophysiology follows a mechanism similar to atherosclerosis, © 2017 American Heart Association, Inc. Abstract-Calcific aortic valve disease (CAVD) is a highly prevalent cardiovascular disorder accounting for a rising economic and social burden on aging populations. In spite of continuing study on the pathophysiology of disease, there remain no medical therapies to prevent the progression of CAVD. The discovery of biomarkers represents a potentially complementary approach in stratifying risk and timing of intervention in CAVD and has the advantage of providing insight into causal factors for the disease. Biomarkers have been studied extensively in atherosclerotic cardiovascular disease, with success as additive for clinical and scientific purposes. Similar research in CAVD is less robust; however, the available studies of biomarkers in CAVD show promise for enhanced clinical decision making and identification of causal factors for the disease. This comprehensive review summarizes available established and novel biomarkers in CAVD, their contributions toward an understanding of pathophysiology, their potential clinical utility, and provides an outline to direct future research in the field. Visual Overview-An online visual overview is available for this article.
C alcific aortic valve disease (CAVD) is a common cardiovascular disorder affecting up to 13% of the US population, 1 which is characterized by thickening and calcification of the aortic valve in the absence of rheumatic heart disease. 2 Aortic stenosis (AS) represents the clinical manifestation of CAVD, occurring when the remodeling of valve tissue is sufficiently severe to result in hemodynamic changes at the aortic valve. Hemodynamic measurements are typically quantified by transthoracic echocardiography and used in conjunction with clinical context for a diagnosis of AS 2 . Aortic sclerosis is a term used to refer to the subclinical manifestation of CAVD: an asymptomatic pathological remodeling of the aortic valve without hemodynamic consequence. Aortic sclerosis may be identified by either qualitative thickening of the aortic valve on echocardiography or aortic valve tissue calcification as identified on computed tomographic imaging. 3 The prevalence of AS increases with age, affecting an estimated 9% of patients aged >80 years. 2 Aortic sclerosis is significantly more prevalent, affecting an estimated 25% to 30% of patients aged >65 years and is estimated to progress to AS at a rate of 2% per year. 3 It is unclear which patients with aortic sclerosis will progress to hemodynamic compromise and AS.
Echocardiography remains the gold standard for diagnosis and evaluation of CAVD; however, echocardiographic parameters for disease severity give limited insight into CAVD pathophysiology and have poor predictive value for the rate of progression from early-to late-stage disease. A potentially complementary approach to stratify risk and timing of intervention in patients with CAVD, as well as to gain greater insight into causal factors for the disease, is the discovery of biomarkers. Biomarkers have been studied extensively in atherosclerotic cardiovascular disease, with some proving additive to risk scores in predicting future cardiovascular events 4 and some being recognized as causal factors in the disease. 5 Research on biomarkers in CAVD is much less robust. Only 1 biomarker, bone natriuretic peptide, has demonstrated clinical utility 6 for CAVD management. Recently, results from a genetic association study implicated a single-nucleotide polymorphism in the LPA gene affecting plasma levels of lipoprotein(a) [Lp(a)] as associated with prevalent CAVD, 7 suggesting Lp(a) as a potential causal factor in CAVD.
This comprehensive review focuses on both established and novel biomarkers in CAVD, summarizing their association with prevalence and progression of CAVD and clarifying the specific biological pathways implicated in the pathogenesis of disease.
involving many interrelated physiological axes that culminate in fibrosis, calcification, and eventually hemodynamic obstruction at the aortic valve. In spite of these shared biological axes and the presence of many similar clinical and biochemical risk factors, CAVD still likely remains a distinct biological entity from atherosclerosis. Indeed, therapies designed to prevent progression of coronary artery disease (CAD) have failed to alter the course of CAVD, and the cellular biology of CAVD lesions when compared with coronary plaque manifest several important differences, for example, a much greater extent of calcification in late-stage CAVD with proportionally fewer lipid deposits relative to late-stage CAD. 8 Disease outcomes also differ, with CAVD manifesting greater calcium plaque stability relative to CAD, where late-stage plaques are prone to rupture and can result in the acute coronary syndrome.
Clues to the unique biology underlying the development and progression of CAVD derive from large population studies, which have determined many risk factors for the disease, including male sex, hypertension, Lp(a) levels, tobacco use, and low-density lipoprotein-cholesterol (LDL-C).
2 Biomechanical stress is also recognized to play a significant role in the initiation and progression of the disease. Individuals manifesting a bicuspid aortic valve morphology, which is hypothesized to result in a greater degree of biomechanical stress at the valve, constitute almost half of cases of severe AS requiring aortic valve replacement (AVR) surgery. 9 Similarly, systemic disorders of calcium and phosphate regulation may influence premature CAVD. Patients with chronic or end-stage kidney disease are particularly susceptible to an accelerated disease course.
The pathophysiology of disease progression for CAVD provides a useful framework to organize the vast number of existing biomarker studies. A simplified working model for the pathophysiology of CAVD is presented in the Figure. The largest biomarker studies in CAVD are summarized in the Table. Biomarkers and their associations with prevalence and progression of CAVD are summarized in Table I in the onlineonly Data Supplement.
Lipid Metabolism
In a manner similar to atherosclerosis, plasma lipoproteins containing apoB (apoB lipoproteins) are thought to play a significant role in the pathogenesis of CAVD. 15 Mechanical stress from shear blood flow across the aortic valve and resulting endothelial damage enable the penetration and entrapment of apoB lipoproteins into the valvular endothelium. These trapped particles undergo oxidative modification resulting in highly cytotoxic oxidized lipid deposits in the valve interstitium. Indeed, histological examination of surgical samples demonstrate that inflammatory cell infiltrates, lipoproteins, and lipids are all present in stenotic aortic valve tissue. 16 Many clinical risk factors are similar between CAVD and CAD including diabetes mellitus and hypercholesterolemia. 
Low-Density Lipoprotein-Cholesterol
Although smaller studies are inconsistent in demonstrating a statistically significant difference in serum lipids with CAVD, 17 the largest case-control studies generally agree that patients with AS have higher levels of circulating total serum cholesterol 12 and LDL-C. 18 An association between total cholesterol and CAVD persists during the earliest stages of aortic valve disease, with 2 case-control studies demonstrating that patients with valve thickening, but without hemodynamic obstruction, have significantly higher total serum cholesterol relative to patients without disease. 19, 20 Data on total cholesterol and LDL-C in their capacity to predict progression of CAVD are less robust, but generally fail to show an association. In several studies ranging from 59 to 156 patients having CAVD, with echocardiographic measurements of disease severity involving up to 3.7 years of follow-up, no clear relationship was observed. 21, 22 In one of these studies, although hypercholesterolemia was not associated with adverse outcome, 22 patients who underwent valve surgery in the first 3 months were excluded from further analysis-these patients had a significantly higher serum cholesterol level than those not otherwise excluded. 22 Further evidence for a possible association between LDL-C and total cholesterol with progression of disease is apparent in studies evaluating CAVD progression by calcium burden measured with electron beam tomography 23 ; however, studies of this kind are limited by small sample size and relatively short follow-up.
The recognized association between atherosclerosis, cholesterol, and CAVD was the basis for studies evaluating the efficacy of LDL-lowering therapy in retarding CAVD progression. Three large randomized clinical trials were reported between 2005 and 2010 assessing the impact of statins on either AS progression by echocardiographic parameters or outcome using a composite of cardiovascular events. These studies sought to randomize patients with mild to moderate AS to treatment with several different statins. No statistically significant difference was found for any of the measured parameters of disease progression or other cardiovascular outcomes. [24] [25] [26] A common criticism for these studies is that medication was started for patients with late-stage disease, leaving open the possibility for earlier intervention, when a potentially greater impact might be made by medications targeting the pathophysiology of early valve lesions. Furthermore, to maintain ethical subject selection, these trials preferentially enrolled individuals with a low LDL-C. Therefore, the impact of statin treatment on AS has only been tested in the subset of individuals with lower LDL-C, who are at potentially lower risk for disease progression and cardiovascular events. Nonetheless, the observed lack of efficacy for statins in preventing progression of clinical AS highlights potential differences in the biological underpinnings for CAVD versus CAD and in the optimal form and timing of medical therapeutic intervention for these 2 disease processes.
Triglycerides
An elevation in plasma triglycerides is independently related to CAD risk, with genetic evidence for a causal role. 27 Evidence is less clear for a role of triglycerides in CAVD. In a study of 1329 patients with aortic sclerosis and 88 patients with AS, no significant difference was observed in circulating triglycerides between cases and CAVD-free controls. 12 In contrast, in a study of 406 patients with aortic sclerosis who presented to the emergency department with chest pain, there was a significant association between high plasma triglycerides and the presence of aortic sclerosis. These results did not control for the presence of CAD, which was significantly prevalent in this population. 
High-Density Lipoprotein-Cholesterol and Cholesterol Efflux Capacity
In contrast to CAD, in which there is a well-replicated and strong association between low high-density lipoproteincholesterol (HDL-C) and prevalence/progression of disease, 29 studies are less clear with regard to an association of circulating HDL-C to CAVD, with stronger results for a relationship between low HDL-C and aortic sclerosis than between low HDL-C and late-stage CAVD. 19, 20 In a study comparing circulating HDL-C between patients with aortic sclerosis (1405 individuals) and patients without aortic valve disease (3709 individuals), HDL-C was significantly lower in patients with CAVD in univariate analysis (P<0.0001). However, the effect size of this relationship was considerably smaller when considered in a multivariate regression model controlling for a variety of clinical and laboratory parameters. 12 Several more recent studies demonstrate a lack of association between HDL-C level and prevalent AS; however, these are limited by small sample size. 30 In contrast, low circulating HDL-C demonstrates a significant association with aortic valve calcium burden. In a study of 5723 patients from the MESA (Multi Ethnic Study of Atherosclerosis) with 211 cases of incident aortic valve calcium measured on electron beam tomography in 2-to 3-year follow-up, low HDL was significantly associated with the presence of aortic valve calcium. 31 In light of data demonstrating that HDL-C efflux capacity is inversely associated with coronary atherosclerotic risk, 32 a study was recently performed addressing HDL functional biomarkers (including cholesterol efflux capacity and lecithin cholesterol acyltransferase activity) in their association with AS. 33 In the fraction of patients who were involved in the biomarker study, a cohort of 86 individuals with AS and 86 age-/sexmatched controls, the authors found no significant difference in HDL-C levels or measures of efflux capacity with prevalent CAVD. Given the small sample size, a definitive conclusion about the lack of association is difficult. Moreover, no patients with aortic sclerosis were studied in this cohort, precluding examination of a potential relationship between cholesterol efflux and early CAVD, where there has already been observed a stronger relationship to HDL-C plasma concentrations.
Lipoprotein(a)
Lipoprotein(a), or Lp(a), is a cholesterol-rich lipoprotein particle which like LDL not only contains apoB 100 but also includes a second protein called apo(a) covalently linked to apoB. Lp(a) is a well-recognized cardiovascular risk factor and has a continuous, independent association with CAD and stroke. 34 Early case-control studies 35 demonstrated a similar strong association of Lp(a) with prevalent CAVD, a result that has been replicated independently in many distinct cohorts. In the largest of these, Stewart et al 12 compared 1329 individuals with aortic sclerosis and 88 patients with AS from the CHS (Cardiovascular Health Study) with CAVD-free controls. After multivariate analysis, Lp(a) maintained a significant and strong association in these patients with prevalent disease. In another large prospective study involving 454 cases of incident AS >20-year follow-up, elevated Lp(a) >90 mg/ dL predicted a 3-fold increased risk of AS. 36 Lp(a) levels are also associated with progression of CAVD. In a study of 220 patients with mild to moderate AS and an average of 3.5 years of follow-up, patients in the top tertile of Lp(a) were found to have a significantly faster rate of progression and an increased risk of AVR and cardiac death. 37 Lp(a) is strongly genetically determined, with >90% of the plasma Lp(a) levels determined by genetic variation at the LPA locus encoding the protein apo(a). Genetic variants in LPA that are associated with Lp(a) levels have been independently associated with CAD, implying a causal role for Lp(a) in coronary atherogenesis. 5 A similar approach has been applied to LPA variants, Lp(a) levels, and CAVD. In a genome-wide association study of 6942 patients, genetic variation at the LPA locus was significantly associated with aortic valve calcification and incident AS 7 . In a mix of 397 patients with aortic valve calcification from the FHS (Framingham Heart Study) and 1338 patients from the AGES-RS (Age Gene/Environment Susceptibility-Reykjavik Study), Lp(a) was differentially expressed relative to those patients without aortic valve calcification and was implicated with genetic variation of the LPA gene between cases and controls such that the causal effect of genetically determined Lp(a) levels was estimated as a 62% increase in the odds of aortic valve calcification per log unit increase in plasma Lp(a) levels. 7 This Mendelian randomization study indicates that Lp(a) has a likely causal role in the pathogenesis of CAVD.
Bone and Mineral Metabolism
Early histological studies in CAVD reveal a spectrum of calcium deposition phenotypes within the aortic valve, from amorphous calcium phosphate accumulations to mature bone with robust marrow elements. 16 Calcium deposition and bone mineralization are well represented in the late-stage CAVD, with the resulting mineralized structures severely impeding normal operation of the aortic valve. The mechanism of bone formation within the valvular interstitium is thought to be because of a differentiation of myofibroblasts, a subdivision of the valvular interstitial cells, into osteoblasts, which coordinate calcification of the valve in a manner similar to new bone formation. Several disorders of mineral metabolism have been observed in CAVD. Vitamin D receptor polymorphisms, for example, demonstrate an association with incident AS, 38 and it has long been recognized that higher serum phosphate concentrations in patients with kidney disease are associated with aortic and mitral valve calcification. 39 Furthermore, valvular calcification represents a potential target for medical therapeutic interventions to slow the progression of clinical AS. The renin-angiotensin system, a biological axis determining the myocardial response to cardiovascular stress and also potentially implicated in the induction of vascular calcification via aldosterone, 40 has recently been implicated as a potential target for the treatment of AS. In a double-blinded, placebo-controlled trial of 100 individuals with moderate to severe asymptomatic AS, angiotensin-converting enzyme inhibition with ramipril led to a modest but significant reduction in left ventricular mass and slowed the reduction of the aortic valve area (AVA).
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Biomarkers of the Vitamin D/ Parathyroid Hormone Axis
Biomarkers for bone and mineral metabolism are often described in the literature independently as 2 distinct subgroups: biomarkers specific for mineral metabolism and biomarkers specific for bone formation and resorption. Although there is overlap between these groups, biomarkers of mineral metabolism generally refer to those implicated in the vitamin D/parathyroid hormone (PTH) axis. These include serum calcium, phosphate, vitamin D, fibroblast growth factor-23, and PTH. The vitamin D/PTH axis biomarkers are among the best studied for an association with CAVD.
Serum levels of ionized calcium and phosphate are tightly controlled via activation of vitamin D by the kidney, secretion of PTH from the parathyroid glands, and generation of fibroblast growth factor-23 by osteocytes. Dysregulation of serum calcium and phosphate is hypothesized to promote development of CAVD, the cellular basis of which remains an active topic of research. Two large case-control studies support an association between high serum phosphate and prevalent CAVD. First, a study of 1938 CHS participants identified patients with aortic sclerosis (1046 individuals), mitral valve calcification (756 individuals), and aortic annulus calcification (853 individuals) by echo. In this cohort, although serum phosphate levels were within the normal range for all patients, higher serum phosphate was positively associated with aortic valvular and annular calcification. In contrast, serum calcium, PTH, and vitamin D were not associated with aortic or mitral valve calcification. 42 These findings were confirmed in a second large case-control study of 6814 MESA participants, 913 of whom had aortic valve calcification present on computed tomographic imaging.
14 In this cohort, higher serum phosphate levels, but not serum calcium, fibroblast growth factor-23, or PTH, were significantly associated with the presence of aortic valve calcium.
Notably these larger studies measure calcium burden of the aortic valve by computed tomographic imaging as a dependent variable to qualify CAVD, and not clinical AS. This distinction is significant when considering that these measures represent potentially different processes occurring with the aortic valve and that calcium burden is not perfectly correlated with severity of AS. Studies focusing on vitamin D/PTH biomarkers with prevalent clinical AS as a phenotype are much smaller in scale, and although a significant association between high serum phosphate and CAVD is maintained, these have conflicting results with regard to the other vitamin D-PTH axis biomarkers of bone and mineral metabolism. In the largest such study, 260 AS patients were compared with 164 age-and sex-matched controls. Stepwise increases in serum calcium, phosphate, PTH, alkaline phosphatase and stepwise decreases in serum 25-OH vitamin D were significantly associated with increasing severity of AS. 43 Differences in associations when qualifying CAVD by alternate modalities underscore the need for larger and prospective studies of patients having clinical AS. Conclusions on potential physiological explanations for a difference in result between studies are confounded in that MESA and the CHS cohorts excluded patients with known cardiovascular disease. Furthermore, an association for these biomarkers with progression of CAVD is lacking. In 1 small retrospective study of 170 patients with AS and paired echo data, higher serum calcium levels were predictive of a faster rate of reduction in the AVA 44 ; however, these results are limited by small sample size and lacking in quantity of follow-up imaging.
Biomarkers of Bone Formation and Resorption
A second subgroup of bone and mineral metabolism biomarkers are those having differential expression in diseases of abnormal bone formation and resorption, including: N-terminal propeptide of human procollagen type I, β-carboxyl-terminal cross-linking telopeptide of type I collagen, osteocalcin, osteopontin, osteoprotegerin, and fetuin-A among others. Procollagen type I is peptide derived from post-translational modification of procollagen molecules and is considered an analog of bone turnover during treatment for osteoporosis. Osteocalcin, a bone matrix protein, is synthesized by osteoblasts and is positively secreted during bone formation. β-carboxyl-terminal cross-linking telopeptide of type I collagen is thought to represent a measure of aged collagen. When collected simultaneously with α-carboxyl-terminal cross-linking telopeptide of type I collagen, β-carboxylterminal cross-linking telopeptide of type I collagen can be used to assess for rapid turnover of bone. Osteopontin, osteoprotegerin, and fetuin-A are inflammatory markers that affect calcium deposition. Osteopontin, a proinflammatory glycoprotein, inhibits osteoblast deposition of calcium. 45 Osteoprotegerin, a known risk factor for progressive atherosclerosis and cardiovascular disease, 46 is a decoy receptor for RANKL (receptor activator of nuclear factor kappa-B ligand) and functions in vivo to inhibit the differentiation of osteoclast precursors. 47 Fetuin-A, a liver-synthesized glycoprotein, functions as a circulating inhibitor of calcification. 48 Several small case-control studies compare an association between these plasma biomarkers and CAVD; there is generally good agreement for a significant association with CAVD prevalence; however, interpretability for these results is limited by small sample sizes. Previous studies demonstrate an inverse relationship between fetuin-A and valvular calcification, for example, in patients with the end-stage renal disease. 49 This relationship persists in populations of patients without kidney dysfunction. In a study of 79 patients with AS and without known kidney disease, Ix et al 50 confirmed that there was a significant and inverted relationship between serum fetuin-A levels and the presence of CAVD. Osteopontin demonstrates a similar strong association to CAVD, with evidence for a stepwise increase in circulating osteopontin levels with increasing severity of AS measured qualitatively by echocardiography. 51 Studies of osteoprotegerin have yielded discrepant results. In 1 study of 68 AS patients and 20 matched CAVD-free controls, circulating levels of osteoprotegerin predicted the presence of CAD; however, they were not associated with prevalent CAVD. 52 In contrast, a smaller study of 38 patients with severe AS demonstrated significantly increased circulating osteoprotegerin with respect to CAVD-free controls. 53 Evidence for the clinical utility of this biomarker is strengthened by a recognized increase in the plasma concentration of osteoprotegerin in individuals with heart failure, highlighting the potential utility for this molecule to predict timing of and outcomes after valve replacement surgery. Indeed, a recent study of 124 individuals with severe AS undergoing valve replacement determined a strong association between osteoprotegerin and left ventricular remodeling. 54 Although results for these biomarkers are consistent with histological evidence for bone metabolism as a significant player in CAVD, the lack of data on a relation between these biomarkers and disease progression makes it difficult to ascertain when in the course of disease that these biomarkers become altered, and where clinical intervention on these pathways might be helpful. Results for progression of CAVD with respect to biomarkers of bone metabolism are limited to 1 small study of 88 patients with follow-up of at least 12 months, in which lower serum fetuin-A levels were not significantly different between patients with no AS, moderate AS, or severe AS 52 . These results highlight the possibility that circulating levels of plasma biomarkers reflecting bone formation and resorption represent a systemic perturbation manifesting with CAVD rather than a valve-specific expression of these proteins.
Inflammation
The past several years have seen an abundance of evidence for the role of inflammation and endothelial dysfunction in atherogenesis. These processes are also represented within aortic valve tissue, consistent with the recognition that CAVD represents an inflammatory state of the valve interstitium similar to that seen in atherosclerosis. 55 In CAVD and atherosclerosis, endothelial disruption is an initiating event thought to promote penetration of the vascular/valvular endothelium by oxidized lipids and inflammatory cells. 56 The combination of oxidized lipids and inflammatory cells within the underlying tissue supports the generation of inflammatory molecules that enable the fibrotic and calcific processes characteristic of the late-stage disease. 16 Although literature on biomarkers of endothelial dysfunction and inflammation is robust for CAD, there have been remarkably few inflammatory biomarkers studied for their association with CAVD. Of these, perhaps the best studied is C-reactive protein (CRP). CRP, an acute phase reactant released by the liver in response to inflammation, is a wellknown biomarker of low-grade inflammation. Elevated serum CRP is an independent predictor of CAD and cardiovascular events. 11 Initial, smaller case-control studies suggested a positive association between prevalent CAVD and circulating CRP; however, these results were limited to surgical populations and cases of advanced AS. 57 To test the predictive power of CRP for CAVD in the general population, a large casecontrol study of 5201 subjects from CHS was followed up for a period of 5 years, during which 9% or 145 patients of an initial 1610 patients with aortic sclerosis developed incident AS. No significant association was found between CRP, baseline aortic sclerosis, or progression from sclerosis to stenosis.
11 Similar outcomes were found in an independent, smaller cohort when using CRP as part of a predictive tool for progression and severity of CAVD. 58 The lack of association between elevated CRP and progression of CAVD in these studies is interesting although the data for CAVD is notably less robust than corresponding literature for CAD. One possibility is that inflammation plays less of a role in early CAVD, which is consistent with data demonstrating that CRP has been shown to be a poor predictor of subclinical coronary atherosclerotic burden.
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Cardiac Remodeling and the Myocardial Consequences of CAVD
Changes in the cellular architecture of the myocardium play a role in progression to the symptomatic phase of AS. Thickening and calcification of the aortic valve tissue eventually affect an increased hemodynamic burden on the heart, with the resulting cardiovascular stress having myocardial consequences such as hypertrophy and cardiomyocyte death. Cardiovascular stress may be inferred with the measurement of certain circulating biomarkers produced by cardiac tissue, including plasma BNP (B-type natriuretic peptide) and cardiac troponin. These biomarkers of cardiac structure and function are potentially informative to the myocardial consequences of CAVD progression and have the greatest potential to impact clinical decision making in the disease. Indeed, the recent European valve guidelines include markedly increased natriuretic peptide levels as a class IIb indication for AVR in severe AS.
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BNP
Plasma BNP and NT-proBNP (its N-terminal pro form) are released by the ventricles of the heart in response to excessive stretching of cardiomyocytes. BNP and NT-proBNP are associated with a variety of cardiovascular disorders with increased serum concentrations portending a poor prognosis. 6 A difference in circulating BNP between patients with AS and matched controls was recognized early in several case-control studies, 61 paving the way for larger studies with the potential for follow-up and comparison before and after surgical treatment. In the largest of these, 1954 patients with moderate or more severe AS by echo were followed up for an average of 3.8 years. Subjects were excluded for the presence of congenital cardiomyopathies or a recent history of acute coronary syndrome in an effort to control for other pathologies driving an increase in BNP expression. BNP clinical activation (a BNP ratio normalized for age and sex) independently predicted mortality after diagnosis irrespective of symptoms and provided incremental power to the survival predictive model. 10 Multiple studies support BNP as a prognostic biomarker in CAVD, 6 and BNP has been studied extensively in many distinct CAVD subpopulations with respect to management decisions in AS. Patients with severe stenosis but who are asymptomatic, for example, represent a subpopulation of patients with CAVD who would benefit from additional risk stratification. These patients have the highest probability of progressive disease, but without symptoms they do not meet an indication for surgical intervention. BNP, therefore, has the potential to provide particularly useful prognostic information. At least 2 studies have been performed, which address the prognostic value of BNP for asymptomatic patients. 62, 63 In the largest of these, a study of 107 patients with asymptomatic severe AS, a risk score calculator incorporating BNP measurement demonstrated a difference in event-free survival after 20 months from 80% for patients in the first quartile to 7% for patients in the fourth quartile. 63 For patients with conflicting information after aortic valve assessment by echocardiography, irrespective of symptomatology, BNP measurements have the potential to refine assessments of severity. Symptom progression, for example, has been well studied in relation to BNP and NT-proBNP. In the largest such study, 361 patients with various degrees of AS severity as measured by echo were followed up for an average of 2 years. NT-proBNP was found to increase with the grade of AS severity and New York Heart Association class although with some overlap between classes. 64 At least 5 studies support the assertion that BNP measurements are higher in symptomatic patients with severe disease relative to asymptomatic patients. 6 A frequent difficulty in managing patients with AS is differentiating patients with low flow, low gradient severe aortic stenosis from those with an AVA who corrects on stress testing with dobutamine (a condition referred to as pseudosevere AS 66 underscoring the need for a more sophisticated means of surgical prognostication.
Before the advent of transcatheter AVR, many studies were performed, validating BNP as a clinical measurement with prognostic value for surgical AVR. For example, in a study of 144 patients undergoing open AVR, NT-proBNP levels had a higher postoperative predictive value than did EuroSCORE. 67 The same has held true for transcatheter AVR; in a cohort of 1097 patients from the PARTNER trial (Placement of Aortic Transcatheter Valves), it was found that an increase in BNP at 30 days from baseline was independently associated with 1-year mortality. 13 However, there remains controversy on the prognostic value of BNP measurements in transcatheter AVR, with several studies suggesting that BNP does not accurately prognosticate outcomes in these patients.
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Troponin Cardiac troponin is a standard for detection of myocardial damage and has been reported to predict death and the first cardiovascular event in men otherwise free from cardiovascular disease. 69 In CAVD, hemodynamic obstruction can result in left ventricular failure and progressive cardiomyocyte death and hypertrophy, which may be detected by cardiac troponin assays. In a study of 131 patients with AS followed up for a median of 10.6 years, plasma troponin concentrations were found to be significantly associated with AVR or cardiovascular death (hazard ratio 1.77) independent of age, sex, systolic ejection fraction, or AS severity. 70 Subjects were excluded from this study if they had any major pathology hypothesized to promote myocardial cell death beyond clinical AS, for example, prevalent CAD or a history of acute coronary syndrome. Consistent with these results, in a recent study of 147 patients with asymptomatic AS, cardiac troponin was validated as one of several variables associated with midwall fibrosis of the myocardium as part of a clinical risk score to predict cardiovascular events (including cardiovascular death, heart failure, new angina, dyspnea, or syncope), with a sensitivity and specificity of 98%.
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Extracellular Matrix Remodeling
Long-standing increases in the left ventricular pressure that accompany severe AS often result in extensive remodeling of the left ventricle. On a cellular level, this involves pathological modification of the extracellular matrix. Biomarkers of extracellular matrix remodeling are increased in severe AS. Fibulin-1 is a calcium-binding extracellular matrix glycoprotein associated with elastin fibers within the cardiovascular tissue. Fibulin-1 is thought to contribute to the progression of tissue remodeling in cardiovascular diseases and after myocardial infarction. To test the potential association between fibulin-1, myocardial strain, and CAVD, 374 subjects with mild to moderate AS who were enrolled in the Simvastatin and Ezetimibe in Aortic Stenosis study, which excluded any individual with a history of CAD or congenital cardiomyopathies, were followed up for 4 years with sequential measurements of fibulin-1 and NT-proBNP. Fibulin-1 was found to be significantly and inversely correlated with AVA index at baseline, 1-year follow-up, and at 4-year follow-up 72 . Furthermore, higher fibulin-1 levels were significantly and positively associated with NT-proBNP levels at all time points, particularly at lower AVA indexes.
Conclusions
As the population ages, CAVD prognostication and management will invariably become an issue of increasing relevance. Although the management of severe, symptomatic AS is clear, decision making for patients with less severe disease remains an imperfect science. Echocardiography will remain the primary modality of the severity of AS with other imaging modalities adding further value. However, as the data on the prognostic efficacy of serum biomarkers are further elucidated, there is the potential that a panel of these and other yet unmeasured biomarkers may prove useful in clinical decision making. Potential utility of such a panel of biomarkers in CAVD includes screening for early aortic valvular disease, identifying which patients are most likely to progress to severe disease and the differentiation of moderate from severe disease in low flow states.
Biomarkers are especially important considering the potential for future preventative therapies for CAVD. Although no medication has yet demonstrated efficacy in slowing or reversing the course of the disease, data on the association of biomarkers of atherogenesis to the early stages of CAVD suggest that the recent randomized clinical trials of statins may have failed as medication was started too late in the disease course. Biomarkers have played an important role in identifying causal factors of CAVD, most notably for Lp(a). With the advent of a new powerful class of drugs, proprotein convertase subtilisin/kexin type 9 inhibitors that reduce both LDL-C and Lp(a), understanding the relationship of Lp(a) to progression of aortic valvular disease is even more important.
In spite of a growing number of biomarkers implicated in CAVD, there remain many obstacles along the road from biomarker discovery to the development of a successful test for use in routine clinical practice. In an editorial on the state of biomarker research in 2011, it was pointed out that technologies such as proteomics and DNA microarrays have contributed >150 000 articles documenting thousands of biomarkers, with fewer than 100 of these being validated for clinical research. 73 In the literature on biomarkers in CAVD, the vast majority of studies have had a limited sample size, and larger studies have measured a limited number of biomarkers, with the result that after years of research, only 1 biomarker has proven clinically useful in CAVD. Biomarker studies in CAVD are further limited by the inability for commonly used diagnostic tests, such as echocardiography or computed tomography, to measure underlying biological disease activity. To overcome these hurdles, detailed assessments of large clinical samples are needed. A properly powered cohort of AS patients with longitudinal follow-up, sufficient phenotypic information, and banked samples of blood and tissue to assess the role of biomarkers in predicting disease progression should be an important goal for future research.
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